BiohavenBHVN
About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Employees: 239
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
134% more call options, than puts
Call options by funds: $94.5M | Put options by funds: $40.5M
113% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 24
46% more capital invested
Capital invested by funds: $2.94B [Q2] → $4.3B (+$1.37B) [Q3]
25% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]
12% more funds holding
Funds holding: 226 [Q2] → 253 (+27) [Q3]
4% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 80
4.54% less ownership
Funds ownership: 95.64% [Q2] → 91.1% (-4.54%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target | 65%upside $59 | Buy Reiterated | 17 Dec 2024 |
RBC Capital Leonid Timashev 43% 1-year accuracy 19 / 44 met price target | 71%upside $61 | Outperform Reiterated | 4 Dec 2024 |
TD Cowen Tyler Van Buren 36% 1-year accuracy 4 / 11 met price target | 110%upside $75 | Buy Maintained | 13 Nov 2024 |
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target | 90%upside $68 | Overweight Maintained | 3 Oct 2024 |
Financial journalist opinion
Based on 7 articles about BHVN published over the past 30 days